The present results show that HFD and HFD+Fr significantly increased body weight gain in C57BL/6 mice, whereas curcumin exerted a protective effect against this phenotype. This effect appeared to be independent of energy intake, suggesting that curcumin may modulate multiple metabolic pathways involved in the development of obesity rather than simply reducing energy consumption. The causal effect of hypercaloric diets on obesity and metabolic syndrome is widely supported in animal models (
15-
18). Evidence also suggests that the endocannabinoid system may participate in the development of both obesity and cognitive impairment (
1,
5,
19), whereas curcumin may exert beneficial effects by reducing oxidative damage in tissues such as the brain (
8), liver, heart, kidney, and intestine (
9,
17). Ghelani et al. (
20) reported a significant reduction in food consumption in rats treated with different concentrations of curcumin (50, 100, and 150 mg/kg). A 2021 study (
21) reported that curcumin (100 mg/kg) prevented 53% of body weight gain (g/week) in 5-week-old male C57BL/6J mice fed a HFD for 10 weeks, an effect attributed to decreased food intake. Li et al. (
16) demonstrated that supplementation with 0.2% curcumin in a HFD improved metabolic disturbances associated with hepatic steatosis and insulin resistance in obese male C57BL/6 mice. These beneficial effects were linked to alterations in gut microbiota composition and its metabolic products. Similarly, Feng et al. (
22) reported that male ApoE (-/-) mice fed a HFD had significantly greater body weight than those receiving the control diet and that curcumin supplementation (0.1% w/w) for 16 weeks significantly prevented body weight gain; no difference in food intake was observed between groups during the experimental period. Therefore, our findings are consistent with these results, showing that curcumin prevents body weight gain without altering energy intake.
Curcumin may also prevent body weight gain by influencing lipid metabolism. A 60% high-fructose diet significantly increased body weight compared with the control diet, and curcumin (200 mg/kg body weight) significantly prevented this increase without affecting food intake; the authors attributed this effect to decreased lipid concentrations through regulation of proteins involved in fatty acid synthesis (
20). Maithilikarpagaselvi et al. (
23) reported that curcumin reduced body weight gain by preventing hyperlipidemia and hepatic steatosis induced by a high-fructose diet in male Wistar rats. Insulin resistance also plays an important role in body weight regulation. It was previously reported that 23-week-old db/db mice treated with curcumin (0.75% w/w) for 8 weeks had less weight loss than the control group without curcumin. These results suggest that curcumin acts as a metabolic regulator that slows weight loss in older mice with uncontrolled diabetes and hyperphagia, perhaps by decreasing insulin resistance. In addition to influencing lipid metabolism and adipocyte differentiation, curcumin may also influence lean mass gain. Curcumin has previously been reported to increase the expression of proteins involved in protein synthesis (
13,
24), supporting the possibility of lean mass gain. However, the percentages of fat and lean mass were not determined in the present study; therefore, it remains unclear whether curcumin’s effect on body weight reflects reductions in fat mass, lean mass, or both.
The endocannabinoid system comprises cannabinoid receptors (CB1R and CB2R), endogenous cannabinoid ligands, and their biosynthetic and degradative enzymes. CB1R and CB2R are expressed in the brain and in some peripheral tissues (
5,
25). In the present study, we evaluated the effects of curcumin on CB1R and CB2R expression and on their ligands, AEA and 2-AG. Hippocampal CB1R and CB2R expression decreased significantly in the HFD+C group compared with the HFD and SD groups. This reduction was accompanied by prevention of body weight gain in the HFD+C group compared with the HFD group, suggesting a potentially beneficial effect of curcumin. A similar trend was observed in mice receiving fructose (SD+C+Fr vs SD+Fr), although the difference was not statistically significant.
These findings are of particular interest because CB1R activation has been associated with increased food palatability and a preference for fat- and/or carbohydrate-rich foods, which can increase body weight gain, adipose tissue accumulation, and hepatic lipogenesis in rodents. Evidence also indicates that high-fructose diets enhance central appetite signaling and impair cognitive function (
26). Moreover, fructose affects enzymes involved in the synthesis and degradation of endocannabinoids in the hypothalamus. For example, fructose consumption has been shown to increase body weight gain and mRNA expression of fatty acid amide hydrolase while downregulating phospholipase C (
27).
In contrast, evidence suggests that hypothalamic stimulation of CB2R increases energy expenditure and promotes normal weight, whereas blocking CB2R with an antagonist increases food consumption, similar to the effect observed when CB1R is stimulated. In humans, administration of the CB1R antagonist rimonabant has been suggested to decrease appetite and body weight, consistent with observations in rodents (
7). The crucial role of the endocannabinoid system in body weight control has also been demonstrated in CB1R/CB2R double-knockout mice. These mice do not increase caloric intake or body weight gain on a HFD and are resistant to obesity, possibly because of loss of CB1R or an interactive effect of both receptors (
5,
28). This finding supports our results, in which curcumin decreased CB1R expression and body weight. A HFD has been reported not to alter CB1R density in the rat hippocampus but to decrease AEA levels while increasing 2-AG levels (
11). These findings indicate that HFD-induced changes in the endocannabinoid system affect brain regions involved in the hedonic aspects of feeding and cognitive processes. In the present study, CB1R and CB2R expression was determined in the whole hippocampus rather than in specific regions, which may have masked increases in the CA1 and CA3 regions induced by HFD that could be physiologically relevant to body weight gain. The curcumin-induced reduction in CB1R and CB2R expression may reflect its effects across the entire hippocampus, consistent with the changes detected by western blotting. Curcumin may also contribute to the effects in the HFD+C group by decreasing CB1R expression or blocking the receptor. Evidence suggests that antioxidant activity activates MEK1/ERK1/2 signaling pathways through CB1R and that administration of curcumin nanoparticles in an animal model of induced depression increases CB1R mRNA and protein and p-MEK1 and p-ERK1/2 in the hippocampus (
29). Previous studies have also suggested that curcumin may interact with CB1R and CB2R in a carrageenan-induced pain model in mice (
30); however, direct receptor agonism remains to be fully demonstrated.
With respect to CB2R expression, an unexpected finding was that curcumin decreased CB2R expression in mice fed a HFD, whereas it increased CB2R expression in the SD+C+Fr group. Importantly, both groups had lower body weight than groups receiving only hypercaloric diets. These findings suggest that curcumin decreases CB2R expression when mice consume either a high-fat or a high-fructose diet alone; however, when rodents are exposed to a combined high-fat and high-fructose diet, hippocampal CB2R expression increases. One possible explanation is that curcumin may act as a ligand for CB2R, thereby modulating reward-related pathways and contributing to lower body weight. This effect was not accompanied by decreased energy intake, suggesting that curcumin may instead increase energy expenditure and thereby reduce body weight independently of changes in CB2R expression. In this context, bioinformatic molecular analysis has identified curcumin as a potential CB2R agonist (
24). Curcumin has also been suggested to bind to both CB1R and CB2R (
30). With respect to hippocampal endocannabinoid levels, both AEA and 2-AG were decreased by HFD and HFD+Fr and by curcumin treatment. These reductions could be associated with compensatory changes in hippocampal CB1R and CB2R expression, although this possibility requires further investigation.
Finally, the post hoc power analysis indicated high statistical sensitivity for all evaluated variables, whereas the effect size estimates indicated large to extremely large treatment effects. The largest effects were observed for CB2R and 2-AG, supporting the biological relevance and robustness of the dietary interventions and curcumin-induced changes. Taken together, these findings suggest that the observed effects are robust, biologically meaningful, and unlikely to be attributable to insufficient sample size or random variation.
Collectively, these findings raise new questions regarding the mechanisms underlying the effects of saturated fat and fructose consumption on CB1R and CB2R expression and highlight the need for further studies incorporating multiple metabolic and neurological variables.
5.1. Conclusions
In the hippocampus, intake of HFD and a high-fructose diet, separately or in combination, significantly increased body weight gain. The combined diet had a marked effect on CB1R and CB2R expression and, more importantly, significantly decreased AEA and 2-AG levels. Curcumin supplementation attenuated weight gain and modulated cannabinoid receptor expression in a diet-dependent manner, reducing receptor levels under high-fat conditions while increasing them under combined high-fat and fructose exposure.
5.2. Study Limitations
A key limitation of this study is that protein expression was evaluated in the whole hippocampus rather than in specific hippocampal regions. Analysis of specific hippocampal regions would help clarify the effects of hypercaloric diets and curcumin on cannabinoid receptors. The relatively small sample size is another limitation; therefore, the findings should be confirmed in larger cohorts. In addition, only male animals were included, which limits generalizability to females. Future studies should evaluate both sexes to determine whether sex-specific differences influence the observed effects. Another limitation is that only body weight was determined; the percentages of lean mass and fat were not measured. Cognitive performance was also not assessed. Finally, the lack of blinding in the ELISA and western blot procedures is a limitation and should be considered when interpreting the results. Future research should address these issues and validate the findings in humans.